Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Travis J Carlson

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
The Journal of Antimicrobial Chemotherapy|July 29, 2020
In vitro activity of eravacycline against common ribotypes of Clostridioides difficileEugénie Bassères, Khurshida Begum, Chris Lancaster, et al.
Open Forum Infectious Diseases|August 12, 2021
Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in <i>Clostridioides difficile</i> InfectionAnne J Gonzales-Luna, Abiola O Olaitan, Wan-Jou Shen, et al.
Emerging Microbes & Infections|February 11, 2020
PCR ribotypes of <i>Clostridioides difficile</i> across Texas from 2011 to 2018 including emergence of ribotype 255Anne J Gonzales-Luna, Travis J Carlson, Kierra M Dotson, et al.
Open Forum Infectious Diseases|October 27, 2025
Quantifying Antimicrobial Disposals at Six Community Pharmacies With Longitudinal Medication Disposal Programs: An Underappreciated Component of a One Health Approach to Antimicrobial StewardshipElizabeth Hoskins, Elizabeth M Bickenbach, Margaret Buchanan, et al.
Open Forum Infectious Diseases|January 30, 2020
Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With <i>Clostridioides difficile</i> InfectionTravis J Carlson, Bradley T Endres, Julie Le Pham, et al.
Open Forum Infectious Diseases|March 13, 2020
Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial InfectionsSara Alosaimy, Sarah C J Jorgensen, Abdalhamid M Lagnf, et al.
Open Forum Infectious Diseases|December 13, 2021
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative InfectionsNicholas Rebold, Taylor Morrisette, Abdalhamid M Lagnf, et al.
Jac-Antimicrobial Resistance|January 5, 2023
Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USATruc T Tran, Nicolo L Cabrera, Anne J Gonzales-Luna, et al.
Open Forum Infectious Diseases|August 25, 2021
Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette, et al.
Open Forum Infectious Diseases|April 11, 2025
Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort StudyKaylee E Caniff, Nicholas Rebold, Xhilda Xhemali, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The Journal of Antimicrobial Chemotherapy|July 29, 2020
In vitro activity of eravacycline against common ribotypes of Clostridioides difficileEugénie Bassères, Khurshida Begum, Chris Lancaster, et al.
Open Forum Infectious Diseases|August 12, 2021
Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in <i>Clostridioides difficile</i> InfectionAnne J Gonzales-Luna, Abiola O Olaitan, Wan-Jou Shen, et al.
Emerging Microbes & Infections|February 11, 2020
PCR ribotypes of <i>Clostridioides difficile</i> across Texas from 2011 to 2018 including emergence of ribotype 255Anne J Gonzales-Luna, Travis J Carlson, Kierra M Dotson, et al.
Open Forum Infectious Diseases|October 27, 2025
Quantifying Antimicrobial Disposals at Six Community Pharmacies With Longitudinal Medication Disposal Programs: An Underappreciated Component of a One Health Approach to Antimicrobial StewardshipElizabeth Hoskins, Elizabeth M Bickenbach, Margaret Buchanan, et al.
Open Forum Infectious Diseases|January 30, 2020
Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With <i>Clostridioides difficile</i> InfectionTravis J Carlson, Bradley T Endres, Julie Le Pham, et al.
Open Forum Infectious Diseases|March 13, 2020
Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial InfectionsSara Alosaimy, Sarah C J Jorgensen, Abdalhamid M Lagnf, et al.
Open Forum Infectious Diseases|December 13, 2021
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative InfectionsNicholas Rebold, Taylor Morrisette, Abdalhamid M Lagnf, et al.
Jac-Antimicrobial Resistance|January 5, 2023
Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USATruc T Tran, Nicolo L Cabrera, Anne J Gonzales-Luna, et al.
Open Forum Infectious Diseases|August 25, 2021
Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette, et al.
Open Forum Infectious Diseases|April 11, 2025
Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort StudyKaylee E Caniff, Nicholas Rebold, Xhilda Xhemali, et al.
Pageof 3